Experimental KRAS vaccine may help prevent pancreatic cancer

• Pancreatic cancer is a serious cancer type that can be difficult to catch early.
• One potential target area is a protein called KRAS that can mutate in pancreatic cancer.
• One study in people at risk for pancreatic cancer found that a vaccine that targeted KRAS was safe and produced a good immune response.
• The results point to a way to prevent pancreatic cancer as research moves forward.

Pancreatic cancer accounts for 8% of cancer deaths in the United States, and it is challenging to catch pancreatic cancer early. Finding ways to treat and potentially prevent pancreatic cancer is a critical area of research.

One study evaluated a peptide vaccine in people who were at a high risk for pancreatic cancer. This vaccine targeted the mutated protein, KRAS, which is found in the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC).

The study, which appears in Cancer Discovery, found that using this vaccine to target KRAS mutations produced a long-term immune response. This discovery could lead to a full-fledged strategy to prevent pancreatic cancer.